Anand Patel

Day 10 - outcomes of older adults with TP53m myeloid malignancy

pubmed.ncbi.nlm.nih.gov/41057316/

Day 9 - MRD in NPM1m AML treated with lower-intensity venetoclax-based therapy

pubmed.ncbi.nlm.nih.gov/37647641/

Day 8 - asciminib + dasatinib for Ph+ ALL

pubmed.ncbi.nlm.nih.gov/39374521/

Check our work on disparities in MF outcomes led by @andrewthepalmer.bsky.social! We found:

-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well

www.nature.com/articles/s41...

Day 7 - outcomes in TP53m AML with HMA vs HMA+VEN

www.nature.com/articles/s41...

Day 6 - ldac-clad-ven in patients already treated with HMA plus Ven

haematologica.org/article/view...

Day 5 - aza + ven + revumenib for newly dx NPM1m or KMT2Ar AML

ascopubs.org/doi/10.1200/...

Day 4 - Azacitidine + iadademstat in de novo AML

www.thelancet.com/journals/lan...

How can clinicians identify patients with MPNs whose disease is in the accelerated or blast phase? 🩸

🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:

👉 buff.ly/ygLFHa4 👈

#MPNsm #HemOnc #MedSky #HemeSky #BloodSky

Day 3 - InO followed by blina in older adults with newly-dx B-ALL

ascopubs.org/doi/10.1200/...

Day 2 - outcomes of MPN-AP/BP with IDH mutations!

pubmed.ncbi.nlm.nih.gov/40949768/

Back on inpatient leukemia service for 14 days!

Day 1- ziftomenib in R/R NPM1m AML

pubmed.ncbi.nlm.nih.gov/40997296/

In any other country, if federal agents fired upon journalists when unprovoked — what would we call it?

If federal agents marched down streets demanding papers — what would we say?

Authoritarianism — let’s not pretend it’s something else when it happens in our American cities.

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia MECOM rearrangements (MECOM-r) are acute myeloid leukaemia (AML)-defining, regardless of blast percentage or MECOM fusion partner. We sought to investigate if blast percentage or MECOM-r partner was ....

Informative paper on MECOMr AML highlighting we have a lot of work to do!

onlinelibrary.wiley.com/doi/10.1111/...

interesting study looking at the impact of various demographic features including SES in patients with AML in various eras of AML therapy

haematologica.org/article/view...

This is what it looks like when ICE violates our First Amendment rights.

The current ACIP is not a credible committee. It pains me to say this, but do NOT listen to them for guidance on vaccines. I am an infectious disease doc and will be roundly ignoring their misinformed and anti-scientific guidelines.
Yesterday's spectacle was an insult to vaccinology and science.

Back on the Golf Course Rebuilding His Game, Thanks to a Clinical Study Jack Moorman was diagnosed with acute myeloid leukemia at age 65. He participated in a clinical trial of a new targeted therapy called revumenib, which has kept his cancer in check.

a huge thanks to a patient of mine who was willing to share his story with @theaacr.bsky.social regarding being treated with Aza + Ven + Revumenib as part of the BEAT AML study and to advocate for cancer research funding!

cancerprogressreport.aacr.org/report/survi...

a study in @bloodjournals.hematology.org illustrating that ASXL1 mutations in CML are a bad actor!

ashpublications.org/blood/articl...

How the Trump Administration Is Dismantling America’s Cancer-Research System

Reading today’s big NYT Magazine story made me physically sick

It details how Trump & the men he put in charge of federal research—men like Jay Bhattacharya & RFK Jr—are dismantling cancer research

Not just the US vaccine system—they’re crushing cancer R&D

🎁Link

www.nytimes.com/2025/09/14/m...

Reminder that our study investigating HMA + the LSD1 inhibitor iadademstat for accelerated/blast-phase MPNs is open to enrollment!

clinicaltrials.gov/study/NCT066...

a fascinating @bloodjournals.hematology.org letter highlighting synergy between Bcl-xL inhibition and interferon use in MPNs!

ashpublications.org/bloodadvance...

interesting pre-clinical work looking at venetoclax + ponatinib for asciminib-resistant CML!

www.nature.com/articles/s41...

a study looking at paired samples of chronic-phase MPN and blast-phase!

acsjournals.onlinelibrary.wiley.com/doi/full/10....

This is defensive rhetoric: every word is chosen to rebut some attack or criticism that Jeffries imagines the listener making. It’s intrinsically weak and pathetic.

Offensive rhetoric would be: this is bad, this is outrageous, this is authoritarian. It rebuts by making the stronger case.

Thanks to @rubenmesamd.bsky.social for inviting me to speak about MPN-AP/BP at the 2025 MPN Carolinas Workshop!

CNN headline that reads: "Supreme Court allows Trump to block $783 million in National Institutes of Health grants for now"

The Supreme Court just greenlit Donald Trump gutting nearly $800 MILLION for medical treatments and cures.

Congress approved this funding for a reason: it saves lives.

This is disgraceful, and families will suffer.

useful study demonstrating that lower-intensity AML risk scores are not very effective when HMA + VEN is used in R/R AML but immunophenotyping is helpful!

onlinelibrary.wiley.com/doi/10.1002/...

The perfect day for a post-clinic walk through campus

a very interesting @bloodjournals.hematology.org pre-clinical paper looking at tasquinomod in MPN-BP!

ashpublications.org/bloodadvance...